Publications by authors named "Jacques Simiand"

Claim this Profile
S
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Ronan Depoortere, Denis Boulay, Ghislaine Perrault, Olivier Bergis, Michel Decobert, Jacques Simiand

Neuropsychopharmacology· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
Claudine Serradeil-Le Gal, Sylvain Derick, Gabrielle Brossard, Maurice Manning, Jacques Simiand

Stress· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
Guy Griebel, Jacques Simiand, Jeanne Stemmelin, Claudine Serradeil-Le Gal, Régis Steinberg

Curr Drug Targets CNS Neurol Disord· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
Guy Griebel, Ghislaine Perrault, Jacques Simiand, Caroline Cohen, Patrick Granger

CNS Drug Rev· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Régis Steinberg, Richard Alonso, Liliane Rouquier, Christophe Desvignes, Jean-Claude Michaud, Jacques Simiand

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.
Danielle Gully, Michel Geslin, Laurence Serva, Evelyne Fontaine, Pierre Roger, Jacques Simiand

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
Guy Griebel, Jacques Simiand, Régis Steinberg, Mireille Jung, Danielle Gully

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, Jean Wagnon, Marc Pascal

Proc Natl Acad Sci U S A· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Claudine Serradeil-Le Gal, Jean Wagnon, Jacques Simiand, Guy Griebel, Colette Lacour

J Pharmacol Exp Ther· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis